Hydroxychloroquine Therapeutic effects on COVID19: a systematic review and meta-analysis

Abstract

Objective: To summarize, and prove almost the benefits and hurts of hydroxychloroquine (HCQ) or chloroquine for the treatment or prophylaxis of coronavirus infection 2019 (COVID-19).

Designs: A comprehensive electronic search of the terms relevant to this review to identify the relevant studies.

Setting: Systematic review and meta-analysis study.

Subjects: Articles focusing on HCQ and prophylaxis of COVID-19, published up to Jan 2021.

Intervention: Retrieved articles were subtly studied. Data obtained included the mutual relationship between the HCQ SARS-CoV-2.

Main Outcome Measure: the adequacy of security results from hydroxychloroquine or chloroquine are utilized in any setting in licenses with suspected COVID-19 or at hazard for SARS-CoV-2 disease.

Results: A add-up to 824 articles were screened, and 14 clinical considerations with an add-up to test measure of 5548 (2874 cases and 2674 controls) patients were included. A few clinical ponders illustrated great virological and clinical results with HCQ alone o in COVID-19 patients, even though the thinks about had significant methodological restrictions. A few of the other things about appeared negative comes about with HCQ treatment besides the hazard of unfavorable responses.

Conclusion: Prove the benefits and hurts of utilizing hydroxychloroquine or chloroquine to treat COVID-19 is exceptionally frail and clashing. Be that as it may, clinical utilization ought to either follow the Observed Crisis Utilize of Unregistered Intercessions (MEURI) system or be morally affirmed as a trial as expressed by the World Wellbeing Organization. Security information and information from high-quality clinical trials are direly required.

Keywords: hydroxychloroquine, severe acute respiratory syndrome coronavirus 2, COVID-19, MEURI.